Claim 33, line 1: After "compound" insert -- or pharmaceutically acceptable salt --, and delete "other antiviral".

Claim 34, line 1: After "compound" insert -- or pharmaceutically acceptable salt --, delete "other antiviral".

Claim 37, line 1: After "compound" insert -- or pharmaceutically acceptable salt --.

Claim 38, line 1: After "compound" insert -- or pharmaceutically acceptable salt --.

Claim 39, line 1: After "compound" insert -- or pharmaceutically acceptable salt --.

43. (Amended) A pharmaceutical composition comprising:

a pharmaceutically acceptable carrier, a compound which is [the compound] (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof, and another agent having antiviral activity

wherein the amount of the (+)-enantiomer of [corresponding to] said compound or of said pharmaceutically acceptable salt present in said composition is no more than 5% w/w, relative to the combined weight of the (-) and (+)-enantiomers thereof.

Claim 45, line 2: After "compound" insert -- or pharmaceutically acceptable salt --.

Claim 46, line 2: After "compound" insert -- or pharmaceutically acceptable salt --.

Claim 47, line 1: Change "45" to --46--; and

line 2: After "compound" insert -- or pharmaceutically acceptable salt --.

Claim 48, line 1: Change "composition contains" to --compound is--.

Claim 50, line 2: Change "1-1500" to -- 10 - 1500--.

Please add the following new claims:

--**59.** A method according to claim 25, wherein said compound is (-)-*cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.

60. A method according to claim 26, wherein said compound is (-)-*cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.

61. A method according to claim 60, wherein the amount of said compound is 10-1500 mg.

62. A method according to claim 61, wherein the amount of said compound is 20-1000 mg.

63. A method according to claim 62, wherein the amount of said compound is 50-700 mg.

64. A method according to claim 60, wherein said composition contains an amount of the (+)-enantiomer of no more than 2% w/w.

65. A method according to claim 64, wherein said composition contains an amount of the (+)-enantiomer of no more than 1% w/w.

66. A method according to claim 59, wherein said composition contains an amount of the (+)-enantiomer of no more than 2% w/w.

67. A method according to claim 66, wherein said composition contains an amount of the (+)-enantiomer of no more than 1% w/w.

68. A method according to claim 60, wherein said compound and said agent are administered sequentially.

69. A method according to claim 60, wherein said compound and said agent are administered simultaneously.

70. A method according to claim 60, wherein said compound is administered at a dosage of 0.1-750 mg/kg of body weight per day.

71. A method according to claim 70, wherein said compound is administered at a dosage of 0.5-60 mg/kg of body weight per day.

72. A method according to claim 71, wherein said compound is administered at a dosage of 1-20 mg/kg of body weight per day.

73. A composition according to claim 49, wherein said composition contains 10-1500 mg of said compound or pharmaceutically acceptable salt.

74. A composition according to claim 73, wherein said composition contains 20-1000 mg of said compound or pharmaceutically acceptable salt.

75. A composition according to claim 74, wherein said composition contains 50-700 mg of said compound or pharmaceutically acceptable salt.

76. A composition according to claim 49, wherein said composition contains an amount of the (+)-enantiomer of no more than 2% w/w.

77. A composition according to claim 76, wherein said composition contains an amount of the (+)-enantiomer of no more than 1% w/w.

78. A method according to claim 25, wherein said compound or pharmaceutically acceptable salt and said agent are administered in combination.

79. A method according to claim 26, wherein said compound or pharmaceutically acceptable and said agent are administered in combination.

80. A method according to claim 60, wherein said compound and said agent are administered in combination.

81. A method for treating a human suffering from HIV infection comprising administering to said human a pharmaceutical composition comprising: a compound which is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof, and another agent having antiviral activity,

wherein the amount of the (+)-enantiomer of said compound or of said pharmaceutically acceptable salt present in said composition is no more than 5% w/w, relative to the combined weight of the (-) and (+)-enantiomers thereof.

82. A method according to claim 81, wherein said composition contains (-)-*cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.

83. A method according to claim 81, wherein said agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoietin, ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.

84. A method according to claim 82, wherein said agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoietin, ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.

85. A pharmaceutical composition comprising:

a compound which is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof, and another agent having antiviral activity

wherein the amount of the (+)-enantiomer of said compound or of said pharmaceutically acceptable salt present in said composition is no more than 5% w/w, relative to the combined weight of the (-) and (+)-enantiomers thereof.

86. A composition according to claim 85, wherein said composition contains (-)-*cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.

87. A composition according to claim 85, wherein said agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoietin, ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.

88. A composition according to claim 86, wherein said agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoietin, ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.--